News

Ruggell, Liechtenstein, 30 July 2010- Pantec Biosolutions AG, today announced that its first manufactured product, P.L.E.A.S.E.^® Professional’ received an "honourable mention" at the "red dot award: product design 2010" for its particularly successful and innovative design solutions.

Ruggell, Liechtenstein, 20 July 2010- Pantec Biosolutions AG, a privately-owned company developing innovative technologies for transdermal drug delivery, today announced the closing of a CHF 20 million investment achieved by two financing rounds.

Ruggell, Liechtenstein, 1 June 2010 - Pantec Biosolutions AG, a privately-owned company developing innovative technologies for transdermal drug delivery, today announced that it has received a CE mark in the EU for the new professional product line of the Company’s transdermal delivery device: P.L.E.A.S.E.^® (Painless Laser Epidermal System).

Ruggell, Liechtenstein, 24 February 2010, Pantec Biosolutions AG announced today that it has achieved excellent results in a Phase I clinical trial of a FSH (follicle stimulating hormone) patch used in conjunction with the company’s novel P.L.E.A.S.E.^® (Painless Laser Epidermal System) technology. Although smaller peptides and some proteins have previously been delivered transdermally, this is the first time a protein as large as 32 KDa has been successfully delivered in this way.

Ruggell, Liechtenstein, 15 December 2009 - Pantec Biosolutions AG, announced today that the European Agency for the Evaluation of Medicinal Products (EMEA) has granted SME (Small and Medium Sized Enterprise) status to Pantec Biosolutions. 

Ruggell, Liechtenstein, 24 September 2009 - Pantec Biosolutions AG, a privately-owned company developing innovative transdermal drug delivery products, announced today that it has been granted European Patent No. EP1874213, entitled 'LASER MICROPORATOR' by the European Patent Office.